Rafarma Pharmaceuticals, Inc. (RAFA) Comparison with companies in other sectors?

Rafarma Pharmaceuticals, Inc. has a share price of 93.17M. You can analyze Rafarma Pharmaceuticals, Inc. (RAFA) competitors across different market sectors through stock heatmaps.

What are RAFA's NET and operating margins?

Rafarma Pharmaceuticals, Inc. (RAFA) operating margin is around 0.04, and net profit margin is approximately 0.03 as of the latest reports.

In what way does RAFA's earnings per share (EPS) trend reflect its financial momentum?

Rafarma Pharmaceuticals, Inc. (RAFA) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Rafarma Pharmaceuticals, Inc. is -5.89, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Rafarma Pharmaceuticals, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Rafarma Pharmaceuticals, Inc. like P/E which is 27.88, P/B which is 0.71, and PEG which is 0.20. Compare them with sector averages to evaluate if the stock is priced fairly.

Rafarma Pharmaceuticals, Inc.

RAFA•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$0.09

$0.00(0.00%)

Fundamental Analysis of Rafarma Pharmaceuticals, Inc. (RAFA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.01

P/E Ratio

-5.89

ROE

0.02%

Net Margin

0.03%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.69M

Shares OutstandingTotal number of shares issued

$93.17M

Book Value/ShareNet worth per share

$0.12

Revenue/ShareAnnual revenue per share

$0.10

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.014

Net MarginNet income as percentage of revenue

2.93%

Operating MarginOperating income as percentage of revenue

4.46%

ROEReturn on shareholders' equity

2.49%

ROAReturn on total assets

2.21%

ROCEReturn on capital employed

3.90%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.01

Cash/ShareCash and equivalents per share

$0.001

FCF YieldFree cash flow as percentage of market cap

-9.15%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for RAFAFinancial Ratios Analysis details for RAFA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RAFASector Benchmarking details for RAFA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Rafarma Pharmaceuticals, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Rafarma Pharmaceuticals, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Rafarma Pharmaceuticals, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Rafarma Pharmaceuticals, Inc.

For Rafarma Pharmaceuticals, Inc., essential financial indicators include EPS -0.01, PE -5.89, and ROE 0.02. These key ratios reveal insights into Rafarma Pharmaceuticals, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Rafarma Pharmaceuticals, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Rafarma Pharmaceuticals, Inc.

Metrics like Net Margin 2.93% and ROA 2.21% shed light on how well Rafarma Pharmaceuticals, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Rafarma Pharmaceuticals, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Rafarma Pharmaceuticals, Inc.

Using ratios such as P/B Ratio 0.71 and PEG Ratio 0.20, investors can assess whether Rafarma Pharmaceuticals, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Rafarma Pharmaceuticals, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Rafarma Pharmaceuticals, Inc.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-0.01, provide a snapshot of Rafarma Pharmaceuticals, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Rafarma Pharmaceuticals, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Rafarma Pharmaceuticals, Inc.

Investing in Rafarma Pharmaceuticals, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Rafarma Pharmaceuticals, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;